5OG
Belinostat
Created: | 2015-10-29 |
Last modified: | 2016-07-27 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 36 |
Chiral Atom Count | 0 |
Bond Count | 37 |
Aromatic Bond Count | 12 |
Chemical Component Summary | |
---|---|
Name | Belinostat |
Systematic Name (OpenEye OEToolkits) | (~{E})-~{N}-oxidanyl-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide |
Formula | C15 H14 N2 O4 S |
Molecular Weight | 318.348 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | CACTVS | 3.385 | ONC(=O)C=Cc1cccc(c1)[S](=O)(=O)Nc2ccccc2 |
SMILES | OpenEye OEToolkits | 2.0.4 | c1ccc(cc1)NS(=O)(=O)c2cccc(c2)C=CC(=O)NO |
Canonical SMILES | CACTVS | 3.385 | ONC(=O)\C=C\c1cccc(c1)[S](=O)(=O)Nc2ccccc2 |
Canonical SMILES | OpenEye OEToolkits | 2.0.4 | c1ccc(cc1)NS(=O)(=O)c2cccc(c2)/C=C/C(=O)NO |
InChI | InChI | 1.03 | InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+ |
InChIKey | InChI | 1.03 | NCNRHFGMJRPRSK-MDZDMXLPSA-N |
Drug Info: DrugBank
DrugBank ID | DB05015 |
---|---|
Name | Belinostat |
Groups |
|
Description | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. |
Synonyms | Belinostat |
Brand Names | Beleodaq |
Indication | Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia [A19161]. |
Categories |
|
ATC-Code | L01XH04 |
CAS number | 866323-14-0 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Histone deacetylase | MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRK... | unknown | inhibitor |
UDP-glucuronosyltransferase 1-1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL... | unknown | substrate |
Cytochrome P450 2C8 | MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI... | unknown | inhibitor |
Cytochrome P450 2C9 | MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI... | unknown | inhibitor |
Cytochrome P450 1A2 | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL... | unknown | inducer |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL408513 |
PubChem | 6918638 |
ChEMBL | CHEMBL408513 |
ChEBI | CHEBI:94531, CHEBI:61076 |
CCDC/CSD | IZUCAK, IZUCEO, IZUCIS |